Company news

Cogent Biosciences, Inc. news in 2025

Cogent Biosciences, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis

December 29, 2025

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

December 7, 2025

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

December 5, 2025

Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031

November 10, 2025

Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)

November 9, 2025

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

November 9, 2025

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results

November 3, 2025

Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

November 2, 2025

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 23, 2025

Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib

October 19, 2025

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 28, 2025

Cogent Biosciences Announces Participation in the Citi Biopharma Conference

August 25, 2025

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results

August 4, 2025

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

July 9, 2025

Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

July 7, 2025

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

July 7, 2025

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

July 6, 2025

Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing

June 10, 2025

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

May 28, 2025

Cogent Biosciences Reports First Quarter 2025 Financial Results

May 5, 2025

Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

April 24, 2025

Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

March 24, 2025

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference

March 6, 2025

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

February 26, 2025

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

February 24, 2025

Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

February 9, 2025

Cogent Biosciences to Participate in the Guggenheim Biotech Conference

January 29, 2025

Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

January 12, 2025

Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

January 7, 2025

Decks in 2025